Related Experiment Video

Updated: May 13, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Controversies in antiepidermal growth factor receptor therapy in metastatic colorectal cancer

Janghee Woo1, Neil Palmisiano, William Tester

  • 1Department of Medicine, Albert Einstein Medical Center, Philadelphia, PA 19141, USA. woojangh@einstein.edu

Cancer
|March 19, 2013
PubMed

Insights

First-line treatment with anti-EGFR monoclonal antibodies (cetuximab, panitumumab) plus chemotherapy shows efficacy in KRAS wild-type tumors. However, recent trials and analyses present conflicting results, necessitating careful consideration of treatment factors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Clinical Trials

Background:

  • Randomized trials (CRYSTAL, OPUS, PRIME) showed efficacy of anti-EGFR antibodies (cetuximab, panitumumab) plus chemotherapy in KRAS wild-type tumors, improving progression-free survival and response rates.
  • However, recent trials (MRC COIN, Nordic VII) reported no added benefit of cetuximab to first-line chemotherapy.
  • Retrospective analyses revealed complex outcomes, including an unexpected association of KRAS G13D mutation with better outcomes in some settings, and conflicting results regarding panitumumab benefit in patients with this mutation.

Purpose of the Study:

  • To critically re-evaluate previous and recent randomized clinical trials and subgroup analyses of anti-EGFR monoclonal antibodies in combination with chemotherapy.
  • To identify key factors influencing treatment outcomes in patients with KRAS wild-type tumors receiving first-line therapy.
  • To discuss anti-EGFR antibody-associated skin toxicity and management strategies.

Main Methods:

  • Review and critical analysis of existing randomized clinical trials (e.g., CRYSTAL, OPUS, PRIME, MRC COIN, Nordic VII).
  • Evaluation of retrospective analyses and pooled data from major clinical trials.
  • Consideration of preclinical data on mechanisms of action and resistance.
  • Analysis of factors such as crossover events and chemotherapy dose reductions.

Main Results:

  • Initial trials demonstrated significant benefits of adding anti-EGFR antibodies to chemotherapy for KRAS wild-type tumors.
  • More recent trials reported a lack of benefit, challenging initial findings.
  • Conflicting data emerged regarding the prognostic and predictive role of specific KRAS mutations (e.g., G13D).
  • Skin toxicity associated with anti-EGFR antibodies and management strategies are significant considerations.

Conclusions:

  • The addition of anti-EGFR monoclonal antibodies to chemotherapy in the first-line setting for KRAS wild-type tumors requires careful consideration of multiple factors.
  • These factors include preclinical data on efficacy and resistance mechanisms, the impact of crossover events on overall survival, and the influence of chemotherapy dose modifications.
  • Further research and critical re-evaluation of trial data are needed to optimize treatment strategies and patient selection.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...